Quick Answer
Alaunos Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $1.39 million for the year ending 2025.
- Alaunos Therapeutics, Inc. showed an increase of +26.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2003 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Historical annual values: Fiscal year 2025: $1.39 million | Fiscal year 2024: $1.09 million | Fiscal year 2023: $6.06 million | Fiscal year 2022: $39.06 million | Fiscal year 2021: $76.05 million | Fiscal year 2020: $115.07 million | Fiscal year 2019: $79.74 million | Fiscal year 2018: $61.73 million | Fiscal year 2017: $70.95 million | Fiscal year 2016: $81.05 million | Fiscal year 2015: $140.72 million | Fiscal year 2014: $42.80 million | Fiscal year 2013: $68.20 million | Fiscal year 2012: $73.31 million | Fiscal year 2011: $104.71 million | Fiscal year 2010: $60.39 million | Fiscal year 2009: $48.84 million | Fiscal year 2008: $11.38 million | Fiscal year 2003: $0.00.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: